Souhaitez-vous accéder aux communiqués récents ?

Easy Environmental Solutions Enters 2026 With Accelerated Global Momentum and a Clear Path to Scale

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel...

First-in-class condensate-modulating small molecule Development Candidate targeting pathogenic TDP-43 condensates in ALS, FTD and traumatic brain injury.

PharmAla inks contract with Ostfold Hospital Trust in Oslo to supply clinical trial in exchange for both cash and a data license

- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim...

Financing supports Phase 2 development of ALV-100, IND filing of ALV-200 and advancement of additional programs across the R&D pipeline ALV-100, a bifunctional GIPR antagonist / GLP-1R agonist,...

Transpire Bio CEO Dr. Xian-Ming Zeng will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2026

Boehringer Ingelheim exercises option to license additional Dark Antigens from a wider array of tumor types, expanding Enara’s eligibility for milestone payments under existing collaboration  Scott...

VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina”), a biopharmaceutical company advancing innovative cancer therapies...

Freiburg im Breisgau, Germany – January 8, 2026 – Eleva, a pioneer in discovering and developing previously inaccessible biologics, today announced the appointment of Dr. Erich Rajkovic, MBA, as Chief...